FDA Import Refusal SCS-9266231-3/51/1 — ASTRAZENECA PHARMA INDIA LTD
The FDA refused shipment SCS-9266231-3/51/1 from ASTRAZENECA PHARMA INDIA LTD (India) on Dec 20, 2021. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- Dec 20, 2021
- Country
- India
- Product Category
- Drugs and Biologics
- Product Code
- 61PCY70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75